Mary DiBiase - 30 Jun 2022 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role
Chief Operating Officer
Signature
/s/ Derek M. Meisner, attorney-in-fact
Issuer symbol
XFOR
Transactions as of
30 Jun 2022
Net transactions value
$0
Form type
4
Filing time
01 Jul 2022, 16:56:49 UTC
Previous filing
27 Jun 2022
Next filing
19 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XFOR Common Stock Sale -1,578 -0.87% 179,609 30 Jun 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.88 to $0.92, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Of the shares of common stock reported, 170,338 shares represent unvested restricted stock units.